Bharat Biotech's plans to advance its tuberculosis vaccine candidate MTBVAC (BBV169) into Phase III clinical trials have been put on hold after the Subject Expert Committee (SEC) on Vaccines sought additional data and protocol revisions before granting further approval.

The proposal was reviewed during the meeting of the SEC - Vaccine held on May 28, 2026. The company presented its Phase III clinical trial protocol along with an interim report from the ongoing Phase II clinical study.

India’s drug regulator has issued a fresh reminder to pharmaceutical manufacturers and other stakeholders regarding the mandatory implementation of pharmacovigilance (PV) systems under the provisions of the Drugs and Cosmetics Act, 1940 and related rules.

Glenmark Pharmaceuticals Ltd. has announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Lacosamide Injection USP 200 mg/20 mL (10 mg/mL) Single-Dose Vials in the United States market. The product is the generic equivalent of Vimpat Injection marketed by UCB Inc. and is indicated for the treatment of seizures associated with epilepsy.